scholarly journals Usefulness of 18f-FDG PET-CT in Staging, Restaging, and Response Assessment in Pediatric Rhabdomyosarcoma

Diagnostics ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1112
Author(s):  
Davide Donner ◽  
Paola Feraco ◽  
Linda Meneghello ◽  
Barbara Rombi ◽  
Lorena Picori ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Pediatric Patients ◽  
Response Assessment ◽  
Response To Therapy ◽  
High Morbidity ◽  
European Guidelines ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Clinical Advances

Rhabdomyosarcoma is the most common soft-tissue sarcoma of childhood. Despite clinical advances, subsets of these patients continue to suffer high morbidity and mortality rates associated with their disease. Following the European guidelines for 18F-FDG PET and PET-CT imaging in pediatric oncology, the routine use of 18F-FDG PET-CT may be useful for patients affected by rhabdomyosarcoma, in staging, in the evaluation of response to therapy, and for restaging/detection of relapse. The European Pediatric Protocols are very old, and for staging and restaging, they recommend only radionuclide bone scan. The 18F-FDG PET-CT exam is listed as an optional investigation prescribed according to local availability and local protocols in the investigations panel required at the end of the treatment. We present two cases highlighting the usefulness of 18F-FDG PET-CT in managing pediatric patients affected by rhabdomyosarcoma, providing some bibliographic references.

PH-0040: A 6-point scale approach to 18F-FDG PET-CT for response assessment in HNSCC: a multicenter study

2020 ◽  
Vol 152 ◽  
pp. S11-S12
Author(s):  
P. Bonomo ◽  
A. Merlotti ◽  
S. Morbelli ◽  
V. Berti ◽  
C. Saieva ◽  
...  
Keyword(s):  
Multicenter Study ◽  
Fdg Pet ◽  
Response Assessment ◽  
Point Scale ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

International consensus on the use of [18F]-FDG PET/CT in pediatric patients affected by epilepsy

2021 ◽  
Author(s):  
Mei Tian ◽  
Yasuyoshi Watanabe ◽  
Keon Wook Kang ◽  
Koji Murakami ◽  
Arturo Chiti ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Pediatric Patients ◽  
International Consensus ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Response assessment in relapsing polychondritis with 18F-FDG PET/CT

2017 ◽  
Vol 36 (2) ◽  
pp. 124-125
Author(s):  
T.K. Jain ◽  
A. Sood ◽  
A. Sharma ◽  
R.K. Basher ◽  
A. Bhattacharya ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Relapsing Polychondritis ◽  
Response Assessment ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

scholarly journals 18F-FDG PET/CT in Restaging and Evaluation of Response to Therapy in Lung Cancer: State of the Art

2020 ◽  
Vol 13 (3) ◽  
pp. 228-237
Author(s):  
Angelo Castello ◽  
Sabrina Rossi ◽  
Egesta Lopci
Keyword(s):  
Lung Cancer ◽  
Treatment Response ◽  
Fdg Pet ◽  
Response To Therapy ◽  
Response Evaluation ◽  
Regional Lymph Nodes ◽  
Treatment Response Evaluation ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Background: Metabolic information provided by 18F-FDG PET/CT are useful for initial staging, therapy planning, response evaluation, and to a lesser extent for the follow-up of non-small cell lung cancer (NSCLC). To date, there are no established clinical guidelines in treatment response and early detection of recurrence. Objective: To provide an overview of 18F-FDG PET/CT in NSCLC and in particular, to discuss its utility in treatment response evaluation and restaging of lung cancer. Methods: A comprehensive search was used based on PubMed results. From all studies published in English those that explored the role of 18F-FDG PET/CT in the treatment response scenario were selected. Results: Several studies have demonstrated that modifications in metabolic activity, expressed by changes in SUV both in the primary tumor as well as in regional lymph nodes, are associated with tumor response and survival. Beside SUV, other metabolic parameters (i.e. MTV, TLG, and percentage changes) are emerging to be helpful for predicting clinical outcomes. Conclusion: 18F-FDG parameters appear to be promising factors for evaluating treatment response and for detecting recurrences, although larger prospective trials are needed to confirm these evidences and to determine optimal cut-off values.

scholarly journals 18F-FDG PET/CT for Response Assessment in Pediatric Sebaceous Carcinoma of the Parotid Gland

Diagnostics ◽  
2020 ◽  
Vol 10 (11) ◽  
pp. 908
Author(s):  
Adrien Holzgreve ◽  
Thomas Pfluger ◽  
Irene Schmid ◽  
Orlando Guntinas-Lichius ◽  
Wolfgang G. Kunz ◽  
...  
Keyword(s):  
Cervical Spine ◽  
Parotid Gland ◽  
Fdg Pet ◽  
Response Assessment ◽  
Sebaceous Carcinoma ◽  
Primary Site ◽  
Epithelial Tumor ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

A 16-year-old male patient underwent 18F-FDG PET/CT staging after multiple surgical resections and radiotherapy of an uncommon metastatic pediatric sebaceous carcinoma of the parotid gland. Initial PET/CT imaging exhibited a recurrent paravertebral metastasis (C4) as well as a metabolically active tumor tissue at the primary site. Follow-up PET/CT after radiotherapy of the cervical spine (C4) and four cycles of chemotherapy with cisplatin and palbociclib revealed complete functional remission in the cervical spine and partial remission at the primary site. This case illustrates the 18F-FDG-uptake behavior and the disease course of a very rare malignant epithelial tumor of the salivary glands.

SU-EE-A3-04: ROI-Based Response Assessment Using Pre- and Post-RT 18F-FDG PET/CT

2007 ◽  
Vol 34 (6Part2) ◽  
pp. 2334-2334
Author(s):  
B Cannon ◽  
D Schwartz ◽  
L Zhang ◽  
L Dong
Keyword(s):  
Fdg Pet ◽  
Response Assessment ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Early metabolic response assessment of breast cancer liver metastases: 4-week posttreatment FDG PET predicts survival after 90Y microsphere radioembolization

2019 ◽  
Vol 58 (03) ◽  
pp. 242-248 ◽  
Author(s):  
Amir Sabet ◽  
Martin Ries ◽  
Yamen Al-Khalaf ◽  
Carsten Meyer ◽  
Christian Rudlowski ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Liver Metastases ◽  
Fdg Pet ◽  
Metabolic Response ◽  
Response Assessment ◽  
Tumor Burden ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct ◽  
Early Metabolic Response

Abstract Aim To evaluate the feasibility of early metabolic response assessment with 18F-FDG PET/CT in patients with breast cancer liver metastases 4 weeks after radioembolization with Yttrium-90 labeled microspheres. Methods 25 patients (mean age 58y, range 40–74) with advanced stage liver metastases of breast cancer were treated with 1.9 ± 0.4 GBq of 90Y-microspheres in the salvage setting and underwent 18F-FDG PET/CT at baseline and 4 weeks post-radioembolization. 14 patients (56 %) had an excessive hepatic tumor burden (> 50 % of total liver volume), 21 patients (84 %) had extrahepatic disease. Liver lesions with the highest SUVmax were selected as target lesions and a cut-off was set at 50 % reduction to separate responders from non-responders. The predictive impact of metabolic response on overall survival (OS) was investigated along with other prognostic factors. Results The median OS in this highly advanced metastatic cohort was 7 months (95 % CI, 5–9). All patients had a reduction in SUVmax (mean ΔSUVmax: –49 ± 26 %) at 4 weeks post-treatment. Patients with > 50 % SUVmax reduction survived longer (median OS 13 mo, 95 % CI 8–18) than the remaining patients (median OS 4 mo, 95 % CI 2–6; p = 0.001). From all investigated baseline factors including age, performance status, and presence of extra-hepatic disease, only the hepatic tumor burden had a significant impact on OS (p = 0.02). Conclusions This is the first preliminary evidence in breast cancer that early post-radioembolization molecular response assessment of treated liver metastases – as early as 4 weeks posttreatment – may predict survival. If confirmed by larger series, FDG PET/CT could be considered for early response-adapted treatment modifications.

Sign in / Sign up

Export Citation Format

Share Document